Back

From ₹51 Cr to ₹1,272 Cr in a year—this Indian biotech’s revenue chart is insane. 💰 Molbio is going public targeting ₹22,000–24,000 Cr valuation. IPO expected in November 2025, raising ₹2,200–2,400 Cr. 🔬 Their Truenat platform, is a battery-power

I invested in three biotech IPOs during the COVID bubble. All of them had "revolutionary technology" and "massive TAM" stories. All three are down 70%+ from IPO price. The problem with biotech investing is that retail investors can't properly evaluat